JP2012506368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012506368A5 JP2012506368A5 JP2011526516A JP2011526516A JP2012506368A5 JP 2012506368 A5 JP2012506368 A5 JP 2012506368A5 JP 2011526516 A JP2011526516 A JP 2011526516A JP 2011526516 A JP2011526516 A JP 2011526516A JP 2012506368 A5 JP2012506368 A5 JP 2012506368A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- imidazo
- tetrahydro
- pyridine
- isopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- WEEUMIAFJMZQBT-UHFFFAOYSA-N (2-chloro-2,2-difluoroethyl) 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound CC(C)C1N(C(=O)OCC(F)(F)Cl)CCC2=C1N=CN2 WEEUMIAFJMZQBT-UHFFFAOYSA-N 0.000 claims 1
- HQYLBAHHQXRLJN-UHFFFAOYSA-N (3-chlorophenyl)methyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound C1CC=2NC=NC=2C(C(C)C)N1C(=O)OCC1=CC=CC(Cl)=C1 HQYLBAHHQXRLJN-UHFFFAOYSA-N 0.000 claims 1
- -1 (3-methyloxetane-3-yl) methyl 4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo [4,5-c] pyridine-5-carboxylate Chemical compound 0.000 claims 1
- UJHBPTGXXAVMQB-UHFFFAOYSA-N (4-chlorophenyl)methyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound C1CC=2NC=NC=2C(C(C)C)N1C(=O)OCC1=CC=C(Cl)C=C1 UJHBPTGXXAVMQB-UHFFFAOYSA-N 0.000 claims 1
- SGZASQNKDIGCAN-UHFFFAOYSA-N (5-chloropyridin-2-yl)methyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound C1CC=2NC=NC=2C(C(C)C)N1C(=O)OCC1=CC=C(Cl)C=N1 SGZASQNKDIGCAN-UHFFFAOYSA-N 0.000 claims 1
- BZLMDWBBPQZXJD-UHFFFAOYSA-N (5-methyl-1,2-oxazol-3-yl)methyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound C1CC=2NC=NC=2C(C(C)C)N1C(=O)OCC=1C=C(C)ON=1 BZLMDWBBPQZXJD-UHFFFAOYSA-N 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- BNWCNSHBXPGXIS-UHFFFAOYSA-N 1,3-thiazol-2-ylmethyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound C1CC=2NC=NC=2C(C(C)C)N1C(=O)OCC1=NC=CS1 BNWCNSHBXPGXIS-UHFFFAOYSA-N 0.000 claims 1
- PJBJKGROWVXEJW-UHFFFAOYSA-N 2,2,2-trichloroethyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound CC(C)C1N(C(=O)OCC(Cl)(Cl)Cl)CCC2=C1N=CN2 PJBJKGROWVXEJW-UHFFFAOYSA-N 0.000 claims 1
- MSBBSWWXUQVURY-UHFFFAOYSA-N 2-(2,2,2-trifluoroethoxy)ethyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound CC(C)C1N(C(=O)OCCOCC(F)(F)F)CCC2=C1N=CN2 MSBBSWWXUQVURY-UHFFFAOYSA-N 0.000 claims 1
- XGYVJPDCZHHEDT-UHFFFAOYSA-N 2-(4-chlorophenoxy)ethyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound C1CC=2NC=NC=2C(C(C)C)N1C(=O)OCCOC1=CC=C(Cl)C=C1 XGYVJPDCZHHEDT-UHFFFAOYSA-N 0.000 claims 1
- XYKAPZXCAKKASW-UHFFFAOYSA-N 2-(dimethylamino)ethyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound CC(C)C1N(C(=O)OCCN(C)C)CCC2=C1N=CN2 XYKAPZXCAKKASW-UHFFFAOYSA-N 0.000 claims 1
- VKNCAJJASMWUGD-UHFFFAOYSA-N 2-phenoxyethyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound C1CC=2NC=NC=2C(C(C)C)N1C(=O)OCCOC1=CC=CC=C1 VKNCAJJASMWUGD-UHFFFAOYSA-N 0.000 claims 1
- MRBONSWYKLRFPQ-UHFFFAOYSA-N 2-pyridin-3-yloxyethyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound C1CC=2NC=NC=2C(C(C)C)N1C(=O)OCCOC1=CC=CN=C1 MRBONSWYKLRFPQ-UHFFFAOYSA-N 0.000 claims 1
- FNBYPCKGRWMBCV-RDJZCZTQSA-N 5-o-benzyl 6-o-methyl (4s,6s)-4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5,6-dicarboxylate Chemical compound N1([C@@H](C(C)C)C=2N=CNC=2C[C@H]1C(=O)OC)C(=O)OCC1=CC=CC=C1 FNBYPCKGRWMBCV-RDJZCZTQSA-N 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- YQXJMNJJWPTZET-YNODCEANSA-N [(2r)-oxolan-2-yl]methyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound C1CC=2NC=NC=2C(C(C)C)N1C(=O)OC[C@H]1CCCO1 YQXJMNJJWPTZET-YNODCEANSA-N 0.000 claims 1
- CPQLUNNNJXPKMS-SFVWDYPZSA-N [(2s)-1-methylpyrrolidin-2-yl]methyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound C1CC=2NC=NC=2C(C(C)C)N1C(=O)OC[C@@H]1CCCN1C CPQLUNNNJXPKMS-SFVWDYPZSA-N 0.000 claims 1
- JYRHKVPVXRNDRJ-YNODCEANSA-N [(3r)-1-methylpyrrolidin-3-yl] 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound C1CC=2NC=NC=2C(C(C)C)N1C(=O)O[C@@H]1CCN(C)C1 JYRHKVPVXRNDRJ-YNODCEANSA-N 0.000 claims 1
- AMIPLQUGEQTRSM-GWCFXTLKSA-N [(3s)-oxolan-3-yl] (4s)-4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound N1([C@H](C=2N=CNC=2CC1)C(C)C)C(=O)O[C@H]1CCOC1 AMIPLQUGEQTRSM-GWCFXTLKSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000018093 autoimmune cholangitis Diseases 0.000 claims 1
- CSFAMDFLKUQBQK-RDJZCZTQSA-N benzyl (4s,6s)-6-(methylcarbamoyl)-4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound N1([C@@H](C(C)C)C=2N=CNC=2C[C@H]1C(=O)NC)C(=O)OCC1=CC=CC=C1 CSFAMDFLKUQBQK-RDJZCZTQSA-N 0.000 claims 1
- XDPADPUVPMVMEV-HOCLYGCPSA-N benzyl (4s,6s)-6-carbamoyl-4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound N1([C@H](C=2N=CNC=2C[C@H]1C(N)=O)C(C)C)C(=O)OCC1=CC=CC=C1 XDPADPUVPMVMEV-HOCLYGCPSA-N 0.000 claims 1
- WDCFTEMOHNOANY-UHFFFAOYSA-N benzyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound C1CC=2NC=NC=2C(C(C)C)N1C(=O)OCC1=CC=CC=C1 WDCFTEMOHNOANY-UHFFFAOYSA-N 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 208000003167 cholangitis Diseases 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 208000023589 ischemic disease Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- HRVFDWZOZHBSJM-UHFFFAOYSA-N oxetan-2-ylmethyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound C1CC=2NC=NC=2C(C(C)C)N1C(=O)OCC1CCO1 HRVFDWZOZHBSJM-UHFFFAOYSA-N 0.000 claims 1
- YYEWOALXGQHVJR-UHFFFAOYSA-N oxolan-3-ylmethyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound C1CC=2NC=NC=2C(C(C)C)N1C(=O)OCC1CCOC1 YYEWOALXGQHVJR-UHFFFAOYSA-N 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- BJLVVNQWHJZXSZ-UHFFFAOYSA-N pyrazin-2-ylmethyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound C1CC=2NC=NC=2C(C(C)C)N1C(=O)OCC1=CN=CC=N1 BJLVVNQWHJZXSZ-UHFFFAOYSA-N 0.000 claims 1
- OMDOZAXSWPRNOK-UHFFFAOYSA-N pyridin-4-ylmethyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound C1CC=2NC=NC=2C(C(C)C)N1C(=O)OCC1=CC=NC=C1 OMDOZAXSWPRNOK-UHFFFAOYSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0801979 | 2008-09-16 | ||
| SE0801979-6 | 2008-09-16 | ||
| US10673408P | 2008-10-20 | 2008-10-20 | |
| US61/106,734 | 2008-10-20 | ||
| PCT/EP2009/062011 WO2010031789A1 (en) | 2008-09-16 | 2009-09-16 | New compounds i |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012506368A JP2012506368A (ja) | 2012-03-15 |
| JP2012506368A5 true JP2012506368A5 (enExample) | 2012-07-12 |
| JP5539989B2 JP5539989B2 (ja) | 2014-07-02 |
Family
ID=41226693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011526516A Expired - Fee Related JP5539989B2 (ja) | 2008-09-16 | 2009-09-16 | 新規化合物ｉ |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US8263616B2 (enExample) |
| EP (1) | EP2334672B1 (enExample) |
| JP (1) | JP5539989B2 (enExample) |
| CN (1) | CN102232073B (enExample) |
| AU (1) | AU2009294660B2 (enExample) |
| BR (1) | BRPI0918602B8 (enExample) |
| CA (1) | CA2737527C (enExample) |
| DK (1) | DK2334672T3 (enExample) |
| EA (1) | EA019167B1 (enExample) |
| ES (1) | ES2440279T3 (enExample) |
| MX (1) | MX2011002581A (enExample) |
| NZ (1) | NZ592238A (enExample) |
| PL (1) | PL2334672T3 (enExample) |
| PT (1) | PT2334672E (enExample) |
| WO (1) | WO2010031789A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2334672E (pt) | 2008-09-16 | 2014-01-02 | Proximagen Ltd | Compostos novos i |
| UA112154C2 (uk) | 2009-09-08 | 2016-08-10 | Біоті Терапіс Корп. | Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів |
| GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| CN102311396B (zh) * | 2010-07-05 | 2015-01-07 | 暨南大学 | 一种吡嗪类衍生物和其制备方法及在制药中的应用 |
| FI20115234A0 (fi) | 2011-03-08 | 2011-03-08 | Biotie Therapies Corp | Uusia pyridatsinoni- ja pyridoniyhdisteitä |
| US9150574B2 (en) | 2011-09-14 | 2015-10-06 | Proximagen Limited | Enzyme inhibitor compounds |
| GB201304526D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| GB201304527D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| US20160113893A1 (en) | 2013-06-12 | 2016-04-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| WO2015189534A1 (en) | 2014-06-12 | 2015-12-17 | Proximagen Limited | Vap-1 inhibitors for treating muscular dystrophy |
| GB201416444D0 (en) * | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New compounds |
| GB201416446D0 (en) * | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New enzyme inhibitor compounds |
| WO2016139909A1 (ja) | 2015-03-02 | 2016-09-09 | 日本電気株式会社 | 復号装置、受信機器、送信機器、送受信システム、復号方法、および復号用プログラムが記憶された記憶媒体 |
| GB201507048D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Treatment of pain |
| GB201507036D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Crystalline enzyme inhibitor compound |
| GB201507031D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | New pharmaceutical salt forms |
| GB201513115D0 (en) * | 2015-07-24 | 2015-09-09 | Proximagen Ltd | New therapeutic compound and use in therapy |
| EP3377493B1 (en) | 2015-11-20 | 2020-04-08 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| CA3007768A1 (en) * | 2015-12-07 | 2017-06-15 | Benevolentai Cambridge Limited | Vap-1 inhibitors for treating pain |
| GB201618029D0 (en) | 2016-10-25 | 2016-12-07 | Proximagen Ltd | New process |
| US20220073525A1 (en) * | 2018-12-28 | 2022-03-10 | Forma Therapeutics, Inc. | Compositions for inhibiting ubiquitin specific protease 1 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4141899A (en) * | 1976-01-07 | 1979-02-27 | Societa' Farmaceutici Italia S.P.A. | 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives |
| JPS5285191A (en) * | 1976-01-07 | 1977-07-15 | Farmaceutici Italia | Novel 4*5*6*77tetrahydroimidazoo *4*55c*pyridine derivative process for preparing same and medicine having antiiulcer antiisecretion and antiicolline activities containing same |
| IT1098015B (it) * | 1978-08-07 | 1985-08-31 | Farmaceutici Italia | Nuovi 4,5,6,7,-tetraidroimidazo-aperta par.quadrata 4,5-c chiusa par.quadrata-piridin-derivati |
| US6908926B1 (en) | 1999-04-16 | 2005-06-21 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| SE0004101D0 (sv) * | 2000-11-09 | 2000-11-09 | Pharmacia Ab | New use |
| AU2002214505A1 (en) | 2000-11-09 | 2002-05-21 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives |
| US6576249B1 (en) * | 2000-11-13 | 2003-06-10 | El Gendler | Bone putty and method |
| PT2334672E (pt) | 2008-09-16 | 2014-01-02 | Proximagen Ltd | Compostos novos i |
-
2009
- 2009-09-16 PT PT97830855T patent/PT2334672E/pt unknown
- 2009-09-16 BR BRPI0918602A patent/BRPI0918602B8/pt not_active IP Right Cessation
- 2009-09-16 EA EA201100391A patent/EA019167B1/ru not_active IP Right Cessation
- 2009-09-16 NZ NZ592238A patent/NZ592238A/xx not_active IP Right Cessation
- 2009-09-16 ES ES09783085.5T patent/ES2440279T3/es active Active
- 2009-09-16 JP JP2011526516A patent/JP5539989B2/ja not_active Expired - Fee Related
- 2009-09-16 CA CA2737527A patent/CA2737527C/en not_active Expired - Fee Related
- 2009-09-16 AU AU2009294660A patent/AU2009294660B2/en not_active Ceased
- 2009-09-16 MX MX2011002581A patent/MX2011002581A/es active IP Right Grant
- 2009-09-16 DK DK09783085.5T patent/DK2334672T3/da active
- 2009-09-16 PL PL09783085T patent/PL2334672T3/pl unknown
- 2009-09-16 EP EP09783085.5A patent/EP2334672B1/en not_active Not-in-force
- 2009-09-16 CN CN200980136970.1A patent/CN102232073B/zh not_active Expired - Fee Related
- 2009-09-16 WO PCT/EP2009/062011 patent/WO2010031789A1/en not_active Ceased
- 2009-09-16 US US13/062,318 patent/US8263616B2/en not_active Expired - Fee Related
-
2012
- 2012-08-06 US US13/567,146 patent/US8569338B2/en not_active Expired - Fee Related
-
2013
- 2013-10-25 US US14/062,969 patent/US9035066B2/en active Active
-
2015
- 2015-04-13 US US14/684,813 patent/US9493457B2/en not_active Expired - Fee Related
-
2016
- 2016-10-27 US US15/335,751 patent/US9890160B2/en not_active Expired - Fee Related
-
2017
- 2017-12-29 US US15/858,407 patent/US10399973B2/en active Active
-
2019
- 2019-07-17 US US16/514,413 patent/US11040969B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6353460B2 (ja) | Ｈｂｖ感染に対する抗ウイルス剤としての官能化ベンズアミド誘導体 | |
| AU2022273631B2 (en) | Lpa receptor antagonists and uses thereof | |
| FI4058445T3 (fi) | Glp-1-reseptoriagonisti ja sen käyttö | |
| HRP20221437T1 (hr) | Agonisti receptora glp-1 i njihova upotreba | |
| JP2021532124A (ja) | Ｎｌｒｐ３インフラマソーム阻害剤 | |
| US6653313B2 (en) | 1,4-dihydropyridine compounds as bradykinin antagonists | |
| TWI627174B (zh) | Ｐ２ｘ７調控劑 | |
| WO2014128655A1 (en) | Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors | |
| AU2022273702B2 (en) | Lpa receptor antagonists and uses thereof | |
| JP2016534146A5 (enExample) | ||
| JP2017521457A5 (enExample) | ||
| JP2016530338A5 (enExample) | ||
| EA019167B1 (ru) | Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы | |
| US10131642B1 (en) | Aldosterone synthase inhibitors | |
| JP2015528488A5 (enExample) | ||
| JP2013544797A5 (enExample) | ||
| JPH05507931A (ja) | Ｈｉｖ―阻害性ベンゼンアセトアミド誘導体 | |
| BRPI0616156A2 (pt) | compostos terapêuticos, composição farmacêutica compreendendo os mesmos e uso | |
| JP2021119142A (ja) | キサンチンをベースとする化合物の調製方法 | |
| RS52916B (sr) | Novi hidroksi-6-heteroarilfenantridini i njihova primena kao pde4 inhibitori | |
| CN106687464B (zh) | 大环rip2激酶抑制剂 | |
| CN120731207A (zh) | 6-烷氧基吡唑并嘧啶化合物及其药学用途 | |
| JP2021073259A5 (enExample) | ||
| US9078899B2 (en) | Pyrazolyl-based carboxamides II | |
| TW201400458A (zh) | （２－雜芳基胺基）琥珀酸衍生物 |